Stuttgart - Delayed Quote EUR

Addex Therapeutics Ltd (APE1.SG)

Compare
7.85
+0.70
+(9.79%)
As of 4:11:45 PM GMT+1. Market Open.
Currency in CHF All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
556.05
1,612.95
1,422.44
2,916.31
3,612.82
Operating Expense
11,633.99
11,894.37
21,942.17
18,422.22
15,856.09
Operating Income
-11,077.95
-10,281.42
-20,519.73
-15,505.91
-12,243.27
Net Non Operating Interest Income Expense
0.46
42.36
-19.65
-57.69
-34.20
Other Income Expense
-1,596.22
-317.29
-264.36
211.69
-581.13
Pretax Income
-12,673.60
-10,556.23
-20,804.21
-15,351.91
-12,858.60
Net Income Common Stockholders
5,404.69
-10,556.23
-20,804.21
-15,351.91
-12,858.60
Diluted NI Available to Com Stockholders
5,404.69
-10,556.23
-20,804.21
-15,351.91
-12,858.60
Basic EPS
6.00
-16.80
-55.20
-54.00
-57.60
Diluted EPS
2.40
-16.80
-55.20
-54.00
-57.60
Basic Average Shares
792.60
619.23
376.54
284.33
222.35
Diluted Average Shares
792.60
619.23
376.54
284.33
222.35
Total Operating Income as Reported
-11,077.83
-10,281.30
-20,520.21
-15,505.92
-12,243.27
Rent Expense Supplemental
--
35.57
47.28
37.51
12.00
Total Expenses
11,633.99
11,894.37
21,942.17
18,422.22
15,856.09
Net Income from Continuing & Discontinued Operation
5,404.69
-10,556.23
-20,804.21
-15,351.91
-12,858.60
Normalized Income
-12,483.06
-10,238.94
-20,539.85
-15,563.61
-12,277.47
Interest Income
22.31
63.96
29.25
5.32
35.31
Interest Expense
21.86
21.61
48.90
63.01
69.50
Net Interest Income
0.46
42.36
-19.65
-57.69
-34.20
EBIT
-12,651.74
-10,534.62
-20,755.32
-15,288.90
-12,789.10
EBITDA
-12,185.71
-10,228.67
-20,432.17
-14,941.29
-12,410.34
Reconciled Depreciation
315.70
305.95
323.14
347.61
378.75
Net Income from Continuing Operation Net Minority Interest
-12,673.60
-10,556.23
-20,804.21
-15,351.91
-12,858.60
Total Unusual Items Excluding Goodwill
-190.54
-317.29
-264.36
211.69
-581.13
Total Unusual Items
-190.54
-317.29
-264.36
211.69
-581.13
Normalized EBITDA
-11,995.17
-9,911.38
-20,167.81
-15,152.98
-11,829.22
12/31/2020 - 3/4/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers